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Stroke is a major cause of death and disability worldwide. It occurs when the blood supply to 
the brain is interrupted. Ischemic stroke is a predominant subtype of stroke, which is caused by 
blockage of a blood vessel via thrombosis, arterial embolism, or cerebral hypoperfusion. 
Unfortunately, there is no effective drug to treat stroke. The purpose of this study is to search 
new targets to treat this disease.  
The Na-K-ATPase is a membrane-bound protein widely expressed in all animal cells. It 
transports three Na+ out and two K+ into cells, thus establishing and maintaining the cross-
membrane gradients of Na+ and K+. These ion gradients are critical for maintaining resting 





, glucose, amino acids, and neurotransmitters across the plasma membrane. In 
addition to the classical ion transporting function, NKA can also relay extracellular ouabain-
binding signaling into the cell, such as MAPK, PLC and IP3 signaling. 
In ischemic stroke, function of NKA is hampered due to energy failure, decreased membrane 
expression, and suppressed activity. Malfunction of NKA contributes to ion dysregulation and 
consequently a series of pathophysiological events in ischemic stroke. It was found that 
stimulating NKA with low-concentration ouabain is protective in ischemic stroke However, 
evidences supporting NKA inhibition as a neuroprotective strategy were also reported. Therefore 
we wonder whether NKA can be a target to treat ischemic stroke. 
An extracellular region 897DVEDSYGQQWTYEQR911 (DR region) was identified in the 
M7/M8 domain of NKA (Xu, 2005). We developed a site-specific antibody (DR-Ab), which can 
activate NKA when it binds to the DR region. On the other hand, hydrogen sulfide, a novel 
gaseous neuromodulator, was found to negatively modulate NKA functions in pulmonary 
ix 
 
epithelial cells and renal tubular epithelial cells. Therefore we synthesized a hydrogen sulfide 
releasing compound, ADTOH-DSS, which dissociates in vitro into a hydrogen sulfide releasing 
moiety (ADTOH), and a known natural neuroprotectant danshensu (DSS). 
In the present study, I examined the effects of these two potential neuroprotectants on 
neuronal damage and NKA activity in both in vitro and in vitro models for ischemic stroke. My 
results showed that both pre- and post-treatment with DR-Ab had protective effects in mice 
subjected to a transient middle cerebral artery occlusion (tMCAO) model and in human neuronal 
SH-SY5Y cells exposed to an oxygen glucose deprivation (OGD) model. These beneficial 
effects were accompanied with restored NKA activity, improved Ca
2+
 handling, decreased 
apoptosis and suppressed inflammation. ADTOH-DSS pretreatment protected SH-SY5Y cells 
from OGD/R-induced injuries dose-dependently, suggesting a potential neuroprotective effect 
against ischemic insults. Unfortunately, it failed to reduce neuronal injuries or modulate NKA 
activity in tMCAO mice, possibly due to low CNS concentration or double-edged effects of 
hydrogen sulfide in ischemic stroke. 
In summary, the current study showed that stimulating NKA with the DR-specific antibody 
may be a novel potential therapeutic effect for ischemic stroke. Besides, it also provides some 
preliminary evidences supporting the potential neuroprotective effects of the novel H2S-slow-
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Chapter 1 Introduction 
1.1 General introduction 
Stroke is a serious disease with high and increasing prevalence. In 2012, it was the second 
most common cause of death after ischemic heart disease, accounting for 6.7 million deaths 
(11.9% of the total) in the world. Stroke was responsible for 102 million disability-adjusted life-
years (DALY) lost worldwide in 2010 (Feigin et al., 2014). 
There are two kinds of stroke, hemorrhagic and ischemic stroke. Hemorrhagic stroke is 
caused by bleeding of blood vessels of the brain.  Ischemic stroke is usually caused by blockage 
of a blood vessel via thrombosis, arterial embolism, or by cerebral hypoperfusion. Ischemic 
stroke predominates among all incidences of stroke, constituting approximately 80% of all 
(Thrift, Dewey, Macdonell, McNeil, & Donnan, 2001). 
In spite of the heavy burden of ischemic stroke, there is no good treatment for it (Donnan, 
Fisher, Macleod, & Davis, 2008). There are only a few therapies proved effective so far. Among 
them, recanalization therapy is a major one. Recanalization aims at clearing vascular blockage 
and restoring blood flow. This is made possible through thrombolysis, surgery or endovascular 
techniques (Donnan et al., 2008). In particular, thrombolysis using intravenous recombinant 
tissue plasminogen activator (rt-PA) is the only FDA-approved drug for acute ischemic stroke 
treatment. It has achieved some success but also associated with many problems and restrictions. 
For example, a large portion of patients are presented to hospital beyond the narrow therapeutic 
time window of rt-PA. Poor eligibility and increased risks of hemorrhage are also problems 
associated with rt-PA (Donnan et al., 2008). 
Neuroprotection is another strategy proposed for stroke treatment, which aims at interfering 
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with one or more pathophysiological processes of the ischemic stroke using neuroprotective 
agents.  So far there is no neuroprotectant proved effective against stroke. And tremendous 
efforts are still dedicated to this field.  
The Na-K-ATPase, also known as Na pump, is a membrane-bound protein widely expressed 
in all animal cells. By using the energy from the hydrolysis of one molecule of ATP, it transports 
three Na
+ 
out in exchange for two K
+
 that are taken in (Morth et al., 2007). Therefore it 
establishes and maintains the high internal K
+
 and low internal Na
+
 concentrations. The 
electrochemical gradient the NKA generates is critical in maintaining resting potential, 





, glucose, amino acids, and neurotransmitters across the plasma membrane (Morth et al., 
2007). In addition to the classical ion transporting function, NKA can also relay 
extracellular ouabain-binding signaling into the cell (Morth et al., 2007), such as MAPK, PLC 
and IP3 signaling. 
In ischemic stroke, blood flow is either temperately or permanently interrupted. This leads to 
a shortage of glucose and oxygen in the tissues being influenced. Neuronal cells almost totally 
rely on aerobic respiration for energy. The ischemia-induced energy failure hampers the ability 




 ions. High concentration of these cations in cells 
may result in membrane depolarization, which promotes activation of synaptic glutamate 
receptors and finally causes excitotoxicity. Thus the malfunction of NKA is a gateway of the 
“ischemic cascades” (Dirnagl, Iadecola, & Moskowitz, 1999). 
The function of NKA is dramatically suppressed in ischemic or hypoxic conditions. But this is 
not totally because the aforementioned energy failure. Indeed, both NKA levels and activity are 
downregulated in models of focal ischemia and traumatic brain injury (Jamme et al., 1997; Jung, 
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Choi, & Kwon, 2007; Tavalin, Ellis, & Satin, 1997). This fact suggests that pharmacologically 
preserving NKA function is possible in the context of partial energy failure in ischemia. Actually 
it has been reported that low-concentration ouabain is able to stimulate NKA activity and exert a 




 (DR region) was identified in the M7/M8 domain of NKA (Xu, 
2005). We developed a site-specific antibody (DR-Ab), which can activate NKA when it binds to 
the DR region (Zheng et al., 2011). And similar to ouabain, signaling transduction independent 
of ion transportation was also found when DR-Ab binds to NKA (Zheng et al., 2011). Our earlier 
studies showed that the DR-Ab was able to increase NKA activity and protected isolated 
ventricular myocytes from ischemia/reperfusion injuries (Zheng et al., 2011). We were therefore 
curious to know whether DR-Ab could also play beneficial effects in ischemic stroke. For this 
reason, I examined the effects of DR-Ab pre- and post-treatment in a transient middle cerebral 
artery occlusion model (tMCAO) in mice, and the roles of DR-Ab pretreatment in glutamate-
induced excitotoxicity. In this study, I found that both pre- and post-treatment with DR-Ab were 
able to ameliorate ischemia/reperfusion-induced injuries in the brain. And according to my data, 
this protective effect was likely associated with restored NKA activity, decreased apoptosis and 
suppressed inflammation. 
Hydrogen sulfide, a novel gaseous neuromodulator, was found to decrease NKA activity in 
pulmonary epithelial cells (Althaus, Urness, Clauss, Baines, & Fronius, 2012; Erb & Althaus, 
2014), and down-regulate NKA function through inducing NKA endocytosis in renal tubular 
epithelial cells (Ge et al., 2014). Although these effects are different from our NKA stimulation 
strategy, we wonder whether hydrogen sulfide has NKA-related effects in ischemic stroke. 
On the other hand, conflicting results have been reported about the role of hydrogen sulfide in 
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the ischemic stroke. Hydrogen sulfide was first found to be detrimental in ischemic stroke, 
supported by observational clinical studies in patients (Wong et al., 2006) and confirmed in mice 
using a permanent MCAO model (K. Qu, Chen, Halliwell, Moore, & Wong, 2006). However, 
later studies using reduced dosages and tMCAO models showed potential beneficial effects of 
hydrogen sulfide (Gheibi et al., 2014; Y. Wang et al., 2014).  
Thus we developed a hydrogen sulfide slow-releasing compound (ADTOH-DSS), and 
examined its effects on cerebral injuries as well as NKA function in ischemic stroke using the 
tMCAO model. This compound derives from linking two components, ADTOH as a hydrogen 
sulfide-releasing moiety, and danshensu as an additional neuroprotective pharmacophore. Both 
hydrogen sulfide and danshensu have been shown to be neuroprotective, we expected a 
combined compound may exhibit better effects. Unfortunately, we did not find therapeutic 
effects of this compound in experiment ischemic stroke. And NKA activity was also not 
significantly influenced by ADTOH-DSS. The possible reasons and interpretations of these 
negative results are discussed in this study. 
In summary, two novel potential neuroprotectants were tested in animal and in vitro models of 
ischemic stroke. Both of them may possibly influence NKA activity in health or pathological 
conditions. Their effects on NKA activity in ischemic situations were studied. And the 




1.2 Ischemic stroke 
1.2.1 Definition 
Stroke is a serious medical condition where the blood supply to the brain is interrupted 
(Donnan et al., 2008). There are two kinds of stroke, hemorrhagic and ischemic stroke. 
Hemorrhagic stroke is caused by bleeding of blood vessels of the brain.  Ischemic stroke is 
caused by a transient or permanent reduction in cerebral blood flow. This is usually caused by 
blockage of a blood vessel via thrombosis or arterial embolism, or by cerebral hypoperfusion. 
Ischemic stroke predominates among all incidences of stroke, constituting approximately 80% of 
all strokes according to a study conducted in Australia (Thrift et al., 2001). 
1.2.2 Epidemiology 
Stroke is a serious disease with high and increasing prevalence. In 2010, there were 
approximately 16.9 million people with first stroke and 33 million stroke survivors worldwide, 
significantly increased since 1990 (68%, 84% increase, respectively) (Feigin et al., 2014). 
Besides, stroke is also a major cause of death and disability in the world. In 2012, it was the 
second most common cause of death after ischemic heart disease, accounting for 6.7 million 
deaths (11.9% of the total) in the world. Disability-adjusted life-years (DALY) lost, defined as 
the sum of life-years lost as a result of premature death and years lived with disability adjusted 
for severity, is commonly used for assessment of disease burden. Stroke was responsible for 102 
million DALY lost worldwide in 2010 (Feigin et al., 2014). Roughly 69% of strokes occurred in 
elder people over 65 years old (Feigin et al., 2014). Due to the aging population, especially in 
developing countries, the stroke burden is expected to increase greatly in the next 20 years, 
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(Donnan et al., 2008). 
1.2.3 Risk factors 
A series of nonmodifiable risk factors have been reported, such as age, gender, race and 
heredity (Dyken, 1997; Goldstein et al., 2011). Age is the single most important risk factor for 
stroke. The chance of having a stroke approximately doubles for each decade of life after age 55 
(Brown, Whisnant, Sicks, O'Fallon, & Wiebers, 1996; Wolf et al., 1992). Gender also has deep 
influences on stroke risks. Generally speaking, stroke is more prevalent in men than in women 
(Brown et al., 1996; Pleis & Lethbridge-Cejku, 2007). But it is age-dependent. Men generally 
have higher age-specific stroke incidence rates than women except for those 35 to 44 years of 
age and those >85 years of age (Kissela et al., 2004; Sacco et al., 1998). The higher stroke 
incidence rates for young women seem to be associated with pregnancy (James, Bushnell, 
Jamison, & Myers, 2005) and use of oral contraceptives (Baillargeon, McClish, Essah, & Nestler, 
2005; James et al., 2005). The increased risk in elder women compared to men may be because 
relatively more men die from cardiovascular disease (ie, competing causes of death) at an earlier 
age than women (Dyken, 1997; Goldstein et al., 2011). Race is another risk factor for stroke. 
Black people have both higher incidences of stroke and higher mortality rates than whites 
(Kissela et al., 2004; Sacco et al., 1998). This phenomenon seems to be explained, but only 
partially, by higher prevalence of hypertension, obesity, and diabetes (Giles, Kittner, Hebel, 
Losonczy, & Sherwin, 1995). Besides, Asians also have high stroke incidence rates (He, Klag, 
Wu, & Whelton, 1995). 
Well-documented modifiable risks factors for stroke include hypertension, diabetes, cigarette 
smoking, cardiac disease, transient ischemic attacks, prior stroke, etc (Dyken, 1997; Goldstein et 
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al., 2011). Hypertension is the single most important modifiable risk factor for ischemic stroke. 
The relative risk of stroke is estimated to be approximately 4 for people whose systolic blood 
pressure is over 160 mm Hg and/or diastolic blood pressure is over 95 mm Hg (Dyken, 1997). 
Diabetes has been proved to be an independent risk factor for stroke with a relative risk from 1.8 
to 3.0 (Allen, 1991). Additionally, diabetes also increases possibility of other risk factors such 
hypertension, obesity, and abnormal blood lipids (Goldstein et al., 2011). Cigarette smoking 
increases risk of ischemic stroke roughly by two folds and in a dose-dependent manner (Shinton 
& Beevers, 1989).It is proved that cessation of smoking reduces stroke risks promptly (Kawachi 
et al., 1993; Wolf, D'Agostino, Kannel, Bonita, & Belanger, 1988). This effect is applicable to all 
age spans, and in both heavy and moderate smokers. Various cardiac diseases such as atrial 
fibrillation (Wolf, Abbott, & Kannel, 1991), mitral stenosis (Dyken, 1997), mitral annular 
calcification (McCrory, Matchar, Samsa, Sanders, & Pritchett, 1995) and so forth are shown to 
significantly increase risks for stroke. Prior stroke and transient ischemic attacks also increase 
incidence ratios of stroke (Wolf et al., 1999).  
1.2.4 Prevention 
Prevention of ischemic stroke aims at reducing probability of stroke incidence via recognition 
and management of risk factors. It can be classified into two categories, primary and secondary 
prevention, based on whether or not the patient has stroke or TIA history (Donnan et al., 2008).  
A declining mortality of stroke is observed in developed countries in the last few years. This 
is largely attributable to improved primary prevention in these countries (Donnan et al., 2008). In 
particular, control of hypertension is an area of great success. The western societies have seen an 
improving availability of blood-pressure-lowering agents since the 1950s (Bornstein, Silvestrelli, 
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Caso, & Parnetti, 2006). Hypertension is the single most important modifiable risk factor for 
ischemic stroke. And management of hypertension is proved effective in primary stroke 
prevention (Lawes, Bennett, Feigin, & Rodgers, 2004). Other primary stroke prevention 
strategies proved useful include use of warfarin for patients with atrial fibrillation (Taylor, Cohen, 
& Ebrahim, 2001), lipid reduction with statins in patients with pre-existing ischemic heart 
disease (Amarenco, Labreuche, Lavallee, & Touboul, 2004), and use of aspirin in women 45 
years or older (Ridker et al., 2005), etc. These strategies have achieved success in developed 
countries in the last decades (Donnan et al., 2008). However, the usage of primary stroke 
prevention in developing countries is still unsatisfactory. Implementation of stroke prevention 
strategies is urgently needed in developing countries because these countries account for about 
two-thirds of nearly 5 million stroke-induced deaths per year (Murray & Lopez, 1997). 
Secondary prevention is the prevention of recurrent stroke. Major advances have been made 
in this field in the last three decades. A variety of secondary prevention strategies are available 
nowadays, such as antiplatelet agents, anticoagulants, and carotid endarterectome, etc (Donnan et 
al., 2008). A widely used antiplatelet agent for secondary stroke prevention is aspirin. Aspirin 
alone can decrease the relative risk (RR) by about 13% (95% CI 4·0–21·0) in patients with TIA 
or minor stroke. This effect is almost doubled when aspirin is used together with extended-
release dipyridamole (Group et al., 2006). Another antiplatelet agent, clopidogrel, is shown 
marginally better than aspirin monotherapy, but seems to have additional beneficial effects in 
preventing cardiovascular comorbidities (Committee, 1996). Thus it is recommended that aspirin 
plus extended-release dipyridamole can be used as the standard treatment, with clopidogrel as an 
alternative when there is aspirin allergy or concurrent symptomatic coronary artery diseases 
(Donnan et al., 2008). High dose antiplatelet agents may cause adverse effects such as 
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hemorrhage. This places a ceiling effect to their usage in stroke prevention, since adverse effects 
may offset beneficial effects at higher doses (Diener, 2006). Warfarin is an anticoagulant 
effective for secondary stroke prevention. It is particularly effective for patients with atrial 
fibrillation. In patients with TIA or minor stroke in combination with atrial fibrillation, warfarin 
is able to reduce RR of recurrent stroke by about 70% (95% CI 0·20–0·57) ("Secondary 
prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. 
EAFT (European Atrial Fibrillation Trial) Study Group," 1993). Warfarin may slightly increase 
the risk for intracerebral hemorrhage (0·3–0·6% per year) age-dependently (Hart, Tonarelli, & 
Pearce, 2005). This risk is elevated by old age and high blood pressure, as well as addition of 
antiplatelet agents. The usage of warfarin is slightly restricted by this adverse effect. In general, 
there are quite a few options of secondary prevention strategies available. And a large portion of 
patients are eligible to at least one of them (Donnan et al., 2008).  
1.2.5 Pathophysiology 
Ischemic stroke triggers a complex sequence of pathophysiological events that finally lead to 
cell death. The major pathogenic mechanisms of this cascade include depletion of ATP, ion 
dysregulation, accumulation of extracellular excitatory amino acids such as glutamate, calcium 
overload, activation of proteolytic processes, accumulation of oxygen free radicals, edema, 
neuroinflammation, increase of vascular permeability, necrosis, apoptosis and so forth (Deb, 
Sharma, & Hassan, 2010; Dirnagl et al., 1999; Doyle, Simon, & Stenzel-Poore, 2008). 
Brain tissue has a relatively high consumption of oxygen and glucose, and depends almost 
exclusively on oxidative phosphorylation for energy production. Focal impairment of cerebral 
blood flow restricts the delivery of substrates, particularly oxygen and glucose, and impairs the 
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energy supply required to maintain ionic gradients. The energy failure leads to membrane 
potential lost and cell depolarization. Consequently, voltage-dependent Ca
2+
 channels become 
activated and excitatory amino acids are released into the extracellular space. The glutamate 
uptake by astrocytes is an energy-dependent process and relies on the cross-membrane sodium 
gradient. Sodium influx causes reversal of the normal process of glutamate uptake by astrocyte 
glutamate transporters (Grewer et al., 2008; Rossi, Oshima, & Attwell, 2000; Szatkowski, 
Barbour, & Attwell, 1990). As a result of its increased release and decreased uptake, glutamate 
accumulates to excessive levels. Accumulation of extracellular glutamate causes activation of N-
methyl-D-aspartate (NMDA) receptors, the alpha-amino-3-hydroxy-5-methyl-4-
isoxazoleproprionic acid (AMPA) and metabotropic glutamate receptors, collectively 
contributing to further Ca
2+
 influx and cell excitation (Ginsberg, 2008).  




 enter the cells abundantly via channels for 
monovalent ions (for example, the AMPA receptor–channel). Water follows passively and leads 
to cytotoxic edema which can kill neurons and astrocytes quickly in the core area of ischemia. 
As a universal second messenger, Ca
2+
 overload is able to activate a series of destructive 
enzymes such as proteases, lipases, and endonucleases that allow release of cytokines and other 
mediators, resulting in the loss of cellular integrity (Dirnagl et al., 1999). 
Another effect of NMDA receptor activation and Ca
2+
 overload is the production of nitric 
oxide (Nandagopal, Dawson, & Dawson, 2001). In cerebral ischemia, the activity of nitric oxide 
synthase (NOS) and the total amount of nitric oxide (NO) present in the brain are elevated, 
resulting in large amounts of NO that may lead to brain injury. Nitric oxide is a free radical and 
reacts directly with cellular components to damage them. Nitric oxide can also react with another 
free radical, superoxide, to produce the highly reactive peroxynitrite. Peroxynitrite causes single 
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strand breaks in DNA, which may activate the process of apoptosis, leading to cell death.  
The production of reactive oxygen species, a normal byproduct of oxidative metabolism, is 
also increased during ischemia. Like NO, they can react with and damage cellular components. 
Injury to the plasma membrane of a cell can lead to the inability to control ion flux, resulting in 
mitochondrial failure. Reactive oxygen species, as well as calcium influx and other factors, can 
also permeabilize the mitochondrial membrane (Mattson & Kroemer, 2003). This leads to 
metabolic failure as well as the release of initiators of apoptosis and DNA damage.  
The structural integrity of the affected brain tissue and blood vessels is damaged during 
cerebral ischemia. This process is mediated by neuroinflammation, epithelial damage and the 
release of various proteases, particularly the matrix metalloproteases (MMP) that degrade 
collagens and laminins in the basal lamina (Rosell & Lo, 2008). The loss of vascular integrity 
leads to a breakdown of the blood-brain-barrier and development of vasogenic edema, which 
allows proteins and other macromolecules to enter the extracellular space, resulting in increased 
extracellular fluid volume and elevated intracranial pressure. This may decrease cerebral blood 
flow, and mass effect causing displacement of brain tissue from one compartment to another (ie, 




1.2.6 Clinical treatment 
A major goal of ischemic stroke treatment is to rescue tissues in the ischemic penumbra. In 
contrast to the core ischemic zone, which is severely damaged and destined for certain death, 
tissues in the penumbra are potentially destined for infarction but not yet irreversibly injured 
(Kelly & Luce, 1993). The penumbra is salvageable for several hours after stroke onset. But the 
area of salvageable tissues may shrink if ischemia continues.  
There are only a few therapies proved effective currently and but more under study (Donnan 
et al., 2008). Among them, recanalization therapies aim at clearing vascular blockage and 
restoring blood flow. This is made possible through thrombolysis, surgery or endovascular 
techniques. In particular, thrombolysis using intravenous recombinant tissue plasminogen 
activator (rt-PA) is the only FDA-approved drug for acute ischemic stroke treatment (Donnan et 
al., 2008). It has achieved some success but also associated with many problems and restrictions 
(see below). Neuroprotection is another strategy proposed for stroke treatment, which aims at 
interfering with one or more processes of the ischemic cascades using neuroprotective agents. So 
far there is no neuroprotectant proved effective against stroke (Majid, 2014). Other therapies also 
suffer from either limited effectiveness or eligibility or both. In general, there is no good cure for 
ischemic stroke, which remains a serious threat to human health. 
1.2.6.1 Recombinant tissue plasminogen activator (rt-PA)    
Thrombolysis using intravenous recombinant tissue plasminogen activator (rt-PA) is approved 
for acute ischemic stroke treatment (Donnan et al., 2008). Tissue plasminogen activator is 
a serine protease found on endothelial cells, which catalyzes the conversion 
of plasminogen to plasmin, causing blood clot to breakdown. Recombinant t-PA works by 
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dissolving the clot and improving blood flow to the part of the brain being deprived of blood 
flow. 
The effectiveness of rt-PA was first reported in 1995 ("Tissue plasminogen activator for acute 
ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study 
Group," 1995). It is the only FDA approved treatment for ischemic strokes, and referred to as the 
golden standard by American Heart Association / American Stroke Association. However, its 
usage is restricted for several reasons (Donnan et al., 2008). First, the therapeutic time window 
for thrombolysis is short. Recombinant r-PA was initially approved for patients within 3 h of 
stroke onset in North America in 1996 and in Europe in 2002. Newer guidelines recommended 
use up to 4.5 hours after symptom onset for eligible patients (Davis & Donnan, 2009). Although 
some trials showed beneficial effects in patients treated beyond in 3-6 h (Clark et al., 1999; 
Hacke et al., 2008; Shobha, Buchan, Hill, & Canadian Alteplase for Stroke Effectiveness, 2011; 
Zhang, Sun, & Ju, 2011), the effectiveness of delayed treatment was uncertain and dropped 
quickly after 3h (Wardlaw et al., 2012). Early treatment is considered as a rule of thumb (Davis 
& Donnan, 2009) and referred to as the “time is brain” paradigm (Saver, 2006). Because of the 
short therapeutic time window, the number of patients who might receive treatment and therefore 
potentially benefit is small. Most stroke centers use rt-PA in only about 5% of stroke patients . 
Prevention of disability is seen in only six patients per 1000 ischemic strokes  and t-PA is not 
very effective in improving mortality (Donnan et al., 2008). Secondly, r-PA may cause 
symptomatic intracerebral hemorrhage which further endangers patients. This is seen in roughly 
6–7% of patients who receives rt-PA treatment (Donnan et al., 2008). And the risk of 
symptomatic intracerebral hemorrhage increases with age, high blood pressure, very severe 
neurological deficits, severe hyperglycemia, and, possibly, with early ischemic changes on CT , 
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which often accompanies with ischemic stroke (Donnan et al., 2008). 
1.2.6.2 Stroke care units (SCUs) 
Management of patients in stroke care units is effective for all stroke subtypes (Donnan et al., 
2008). It reduces mortality by about 20% and also improves functional outcome (Langhorne, 
Williams, Gilchrist, & Howie, 1993). In a community-based epidemiological study, in which all 
patients eligible for possible acute stroke interventions were considered, SCU management had 
the potential to prevent death or disability for around 50 patients for every 1000 strokes, 
compared with about 6 per 1000 with rt-PA and 4 per 1000 with aspirin (Gilligan et al., 2005). It 
is unclear which components of SCU are critical for its effectiveness, though improved blood 
pressure control, early mobilization, and general adherence to best practice are considered as 
important components (Cadilhac et al., 2004; Indredavik, Bakke, Slordahl, Rokseth, & Haheim, 
1999). SCU management has been shown effective in developed countries, and is recommended 
as a priority in future health systems in developing countries (Donnan et al., 2008).   
1.3 Na+-K+-ATPase 
1.3.1 General introduction 
The Na-K-ATPase, also known as Na pump, is the most prominent member of the P-type 
adenosine triphosphatase (ATPase) family (Skou, 1957). It is a membrane-bound protein widely 
expressed in all animal cells. By using the energy from the hydrolysis of one molecule of ATP, it 
transports three Na
+ 
ions out in exchange for two K
+
 ions that are taken in (Morth et al., 2007). 
The electrochemical gradient the NKA generates is critical in maintaining resting potential, 







, glucose, amino acids, and neurotransmitters across the plasma membrane (Kaplan, 2002). 
In addition to the classical ion transporting function, NKA can also relay extracellular ouabain-
binding signalling into the cell (Kaplan, 2002). The sodium-potassium pump was discovered in 
the 1950s by a Danish scientist, Jens Christian Skou, who was awarded a Nobel Prize in 1997. 
1.3.2 Structure and reaction cycle 
NKA comprises a 100 KDa α-subunit, a 55 KDa β-subunit, and a tissue-specific auxiliary 
regulatory subunit of approximately 70-180 residues known as FXYD protein (Toyoshima, 
Kanai, & Cornelius, 2011). The NKA α-subunit consists of three cytoplasmic domains, actuator, 
nucleotide binding, and phosphorylation domains, and ten transmembrane helices (M1-M10) 
(Toyoshima et al., 2011).The α-subunit is the catalytic subunit, responsible for most of the 
enzyme's pumping function. In humans there are four α-isoforms (α1, α2, α3 and α4). The 
sequence differences among the isoforms are minor, and at the present time it is not known if the 
small functional differences (differences in the affinity, phosphoenzyme equilibrium poise, etc.) 
are of functional significance (Jewell & Lingrel, 1991). The α1 is ubiquitously distributed in all 
tissues, while α2/α3 are found mainly in brain, heart and skeletal muscle (Blanco, 2005). The α4 
isozyme is highly expressed in testes and spermatozoids, but it has also been found in skeletal 
muscle tissue (Keryanov & Gardner, 2002; Shamraj & Lingrel, 1994).  
The β-subunit of NKA is a single transmembrane protein with a glycosylated C-terminal 
ectodomain and cytoplasmic N-terminal domain (Toyoshima et al., 2011).There are three β-
isoforms (β1, β2 and β3) in human. They can appear in various combinations with different 
isoforms of α-subunits in a tissue specific manner. The most common combination is α1, α2, α3 
or α4 with β1 (Blanco, 2005). The primary role of the β-subunit is to act as a molecular 
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chaperone. Association of the β-subunit with newly synthesized α facilitates routing to and 
insertion into the plasma membrane, thereby conferring conformational stability on the α-subunit 
(Geering, 2001, 2008). The β-subunit also modulates functional properties of the NKA, 
including cation binding affinity (Geering, 2001) and K
+
-occlusion (Lutsenko & Kaplan, 1993).  
FXYD proteins consist of a single transmembrane helix, an extracellular (N-terminal) part 
that contains the FXYD(Y) motif and a cytoplasmic part containing the phosphorylation sites in 
FXYD1 and FXYD10 (Toyoshima et al., 2011). FXYD proteins are tissue-specific regulators of 




 and ATP 
(Mahmmoud, Vorum, & Cornelius, 2000). FXYD1 has also been demonstrated to associate with 




 exchanger (Cheung et al., 2007) and L-type Ca
2+
-channels (X. Wang 
et al., 2010) in heart. 
The reaction cycle of NKA is explained by the Post-Albers scheme (Albers, 1967; Post, 
Hegyvary, & Kume, 1972) or E1/E2 theory. Here, pumping function is achieved by alternating 
the affinity and the facing of the cation binding sites (Kaplan, 2002). The reaction cycle of NKA 





Figure 1.1. The Na,K-ATPase reaction cycle. The sequence of steps involved in the active 
transport of Na and K ions are shown in the Post-Albers scheme for the reaction cycle. Adapted 





1.3.3 Physiological functions of NKA 
The cross-membrane Na and K gradients are critical for the health and functions of almost all 
animal cells. Since NKA is the only driving force for the establishment and maintenance of these 
gradients, its physiological functions are diverse and crucial. To name a few, NKA plays an 
important role in maintaining resting potential, controlling cell volume, and establishing a 
foundation for secondary active transport. Additionally, NKA is also responsible for relaying 
extracellular signaling into cells, thus regulating intracellular pathways such as MAPK, PLC and 
IP3 signaling. These signaling functions are probably mediated by protein-protein interactions, 
and independent of the ion transporting functions of NKA (Kaplan, 2002). 
1.3.4 NKA and ischemic stroke 
Following the onset of ischemia, cellular ATP levels plummet rapidly. In rat models, ischemia 
causes ATP levels to drop quickly within minutes due to the inhibition of mitochondrial 
respiration (Nicholls & Budd, 2000). Because NKA uses a large portion of the cell‟s energy store, 
its activity becomes especially vulnerable under these conditions. In addition, both NKA levels 
and activity are downregulated in cerebral ischemia (Jamme et al., 1997; Tavalin et al., 1997). It 
is also found that the reduction of NKA activity is at least partially responsible for increased Na
+
 
influx in anoxia (Sheldon, Diarra, Cheng, & Church, 2004). The Na
+
 gradient is crucial for NCX 
to transport Ca
2+
 ions out of cells. Thus malfunction of NKA ultimately impairs the ability of 




 from the cell and results in membrane 
depolarization, which promotes activation of synaptic glutamate receptors. Excessive 
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accumulation of extracellular glutamate further activates glutamate receptors, resulting in 
massive calcium influx through N-methyl-D-aspartate (NMDA) receptors and voltage-dependent 
calcium channels. As a universal second messenger, Ca
2+
 overload is able to activate a series of 
destructive enzymes such as proteases, lipases, and endonucleases that allow release of cytokines 
and other mediators, resulting in the loss of cellular integrity. This chain reaction is known as 
excitotoxicity and a major threat in the acute phase of ischemic stroke (Dirnagl et al., 1999). 
Thus it is reasonable to expect that restoring or stimulating NKA activity may prevent or 
suppress the evolution of this detrimental process. Indeed, it was reported that activation of NKA 
with low-dose cardiotonic steroids protects hippocampus from ischemic injury (Oselkin et al., 
2010).  
However, evidences supporting NKA inhibition as a neuroprotective strategy were also 
reported. For example, it was reported that ouabain pretreatment protected neurons from OGD 
insults (Bruer et al., 1997). Another group showed that cardiac glycosides provided 
neuroprotection against ischemic stroke using a brain slice-based compound screening platform 
(J. K. Wang et al., 2006). Thus the exact role of NKA in ischemic stroke remains unknown. 
1.3.5 DR-antibody 
DR-antibody (DR-Ab) is a novel NKA stimulator developed in recent years. An activation 
site that resides in the M7/M8 domains of NKA α-subunit has been demonstrated (D. I. Lee et al., 





 (DR region). NKA is stimulated when DR-
Ab binds to this region (Zheng et al., 2011). Our unpublished results also showed that DR-Ab 
could stabilize NKA in the plasma membrane, and protect it from endocytosis induced by 
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pathological insults.  
1.4 Hydrogen sulfide 
1.4.1 General introduction 
Hydrogen sulfide (H2S) is a colorless and poisonous gas with an odor of rotten eggs. It is 
slightly soluble in water and acts as a weak acid, dissociating into H
+
 and the hydrosulfide ion 
HS
-
. At body temperature and neutral pH, less than 20% of hydrogen sulfide exists as 
undissociated form in solution (Gong et al., 2011) . 
Hydrogen sulfide was known as a toxic gas. However, as increasing knowledge about the 
biological functions of hydrogen sulfide has been unfold in the last two decades, it has now been 
recognized as another gaseous signal molecule after nitric oxide and carbon monoxide. Extensive 
functions of hydrogen sulfide have been revealed in the cardiovascular, central nervous and other 
biological systems under both physiological and pathological conditions. Hydrogen sulfide is 
expressed at a relatively high concentration in the brain. It facilitates hippocampal long term 
potentiation (LTP) by enhancing NMDA receptor-mediated responses (Abe & Kimura, 1996). It 
also modulates intracellular Ca
2+
 and pH homeostasis in neurons, microglial cells and astrocytes 
(S. W. Lee et al., 2006; Lu et al., 2010; Nagai, Tsugane, Oka, & Kimura, 2004; Yong, Choo, Tan, 
Low, & Bian, 2010). Impaired metabolism of hydrogen sulfide was found in several CNS 
disorders such as Alzheimer‟s disease and Parkinson‟s disease. The plasma hydrogen sulfide 
level was reported to be correlated with long term clinical outcome in stroke patients (Wong et 
al., 2006). These findings suggest that hydrogen sulfide may be involved in the initiation or 
progression of these diseases. More importantly, extensive studies have demonstrated the 
potential therapeutic values of hydrogen sulfide in several CNS diseases such as Alzheimer‟s 
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disease (AD), Parkinson‟s disease (PD), traumatic brain injury and perhaps ischemic stroke as 
well. In these diseases, hydrogen sulfide may act as a neuroprotectant via its anti-oxidant, anti-
inflammatory and anti-apoptotic effects. Although it is  still not clear how hydrogen sulfide 
exerts these functions at the molecular level, a series of studies suggest that hydrogen sulfide 
modifies specific Cys residues in proteins through the formation of a persulfide (-SSH) bond, 
and this modification has been termed as protein sulfhydration. Sulfhydration may change the 
conformation and consequently the activities of target proteins, although it‟s still uncertain how 
much this mechanism can explain the multiple biological effects of hydrogen sulfide. 
1.4.2 Metabolism  
Three sources of hydrogen sulfide biosynthesis have been identified. Hydrogen sulfide is 
synthesized by cystathionine -synthase (CBS), cystathionine -lyase (CSE) or cooperation of 3-
mercaptopyruvate sulfurtransferase (3-MST) together with cysteine aminotransferase (CAT). 
CBS catalyzes the -replacement reaction where Cys reacts with Hcy and produces cystathionine 
and hydrogen sulfide. CSE catalyzes the reaction of Cys, producing hydrogen sulfide and serine 
as a byproduct. 3-MST and CAT mediate the catabolism of Cys and produce sulfane sulfur, 
which releases hydrogen sulfide when reduced by physiological reducing reagents like 
thioredoxin. In the central nervous system, the CBS pathway is considered to be the predominant 
source of endogenous hydrogen sulfide (Gong et al., 2011). However, in the CBS knockout mice, 
similar level of hydrogen sulfide was still found in the brain tissue even in the absence of 
pyridoxal-5'-phosphate (PLP). These data suggest that 3-MST is also an important PLP-
independent pathway to produce endogenous hydrogen sulfide in brain. 
The metabolic fate of hydrogen sulfide in cells is not fully understood yet. It is proposed that 
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hydrogen sulfide‟s catabolism may involve chemical reactions such as oxidation to sulfate(Kabil 
& Banerjee, 2014), methylation to methanethiol and dimethyl sulfide and reactions with metallo- 
or cysteine-containing proteins(Gong et al., 2011). Hydrogen sulfide can also be stored in tissues 
as bound sulfane sulfur, including polysulfides and persulfides, and released in response to 
physiological/pathological stimulations (Ishigami et al., 2009; Y. Kimura et al., 2013).  
1.4.3 Hydrogen sulfide as a neuromodulator  
With increasing knowledge about its role in the central nervous system in the last decades, 
hydrogen sulfide has been recognized as a neuromodular. In 1996, Kimura‟s group first reported 
that hydrogen sulfide facilitated hippocampal long term potentiation by enhancing NMDA 
receptor-mediated responses (Abe & Kimura, 1996). Later, they reported that this effect was 
possibly mediated by the cAMP/PKA pathway (H. Kimura, 2000). According to these results, 
the NMDA receptor was activated when its subunits were directly phosphorylated by protein 
kinase A (PKA) at specific sites, which mediated excitatory postsynaptic currents.  Hydrogen 
sulfide activated adenylyl cyclase and increased cAMP production, which may boost the activity 
of PKA and consequently NMDA phosphrylation. Another hypothesis was also described by 
Kimura. Since the activity of NMDA receptors was enhanced when its cysteine disulfide bonds 
were reduced (Aizenman, Lipton, & Loring, 1989), hydrogen sulfide may contribute to NMDA 
activation via reducing the cysteine disulfide and sulfhydrating the cysteine residues (H. Kimura, 
2013). However, further investigation is needed to confirm this hypothesis. 
Hydrogen sulfide also regulated intracellular Ca
2+
 level in various cell types in the brain. 
Kimura‟s group showed that hydrogen sulfide increased intracellular Ca2+ and induced 
Ca
2+





 concentration by inducing Ca
2+
 influx from extracellular space and, to a 
lesser extent, releasing Ca
2+ 
from its intracellular stores. Similarly, our group also found that 
hydrogen sulfide induced elevation of intracellular Ca
2+ 
concentration in microglial cells (S. W. 
Lee et al., 2006) and neuronal SH-SY5Y cells (Yong et al., 2010).  It seems that both 
cAMP/PKA and PLC/PKC pathways also contributed to the calcium regulatory effect of 
hydrogen sulfide in neuronal cells (S. W. Lee et al., 2006; Yong et al., 2010). As intracellular 
calcium acts as a universal second messenger in cells, hydrogen sulfide‟s effects on Ca2+ may 
exert deep and extensive influences on a variety of intracellular processes. However, the 
biological significance and detailed mechanisms are still open to further investigation. 
Hydrogen sulfide was reported to modulate adenylyl cyclase activity and influence cAMP 
level in cells. Kimura showed that hydrogen sulfide increased the production of cAMP in the 
primary cultured brain cells, neuronal and glial cell lines, and Xenopus oocytes(H. Kimura, 
2000). This effect was proposed as the mechanism for the effect of hydrogen sulfide on NMDA 
receptors and the induction of hippocampal LTP. Interestingly, our group found that hydrogen 
sulfide treatment significantly reversed forskolin-induced cAMP elevation in cardiac myocytes 
(Yong, Pan, Hu, & Bian, 2008), vascular smooth muscle cells(Lim, Liu, Khin, & Bian, 2008), 
As4.1 cells(Lu, Liu, Ho, Tiong, & Bian, 2012) and SH-SY5Y cells (Nagpure & Bian, 2014), and 
opioid withdrawal-induced cAMP rebound in SH-SY5Y cells (H. Y. Yang, Wu, Wood, 
Whiteman, & Bian, 2014). These data suggest that hydrogen sulfide may produce dual effects on 
cAMP production in brain cells. On the one hand, hydrogen sulfide may stimulate AC at its 
resting status by modification of AC structure directly or secondary to other signaling pathways. 
On the other hand, hydrogen sulfide may also block the association between forskolin and AC 
and therefore inhibit the effect of forskolin. This is probably mediated by sulfhydration of 
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cysteine residues in the forskolin binding site in AC. More experiments are warranted to confirm 
this hypothesis and to study the underlying molecular mechanisms.  
Hydrogen sulfide also regulates intracellular pH in primary cultures of rat microglia and 
astrocytes. NaHS in the range from 10 to 200 µM decreased intracellular pH in a concentration-




 exchanger but 




 exchanger. As intracellular pH homeostasis is an important basis for the 
normal physiological functions of cells and a critical factor in pathological conditions such as 
hypoxia and ischemia, it is reasonable to speculate that the regulatory effects of hydrogen sulfide 
on intracellular pH may have significant roles in both health and diseases. 
1.4.4 Roles of hydrogen sulfide in ischemic stroke 
Conflicting results have been reported about the role of hydrogen sulfide in the ischemic 
stroke. Chen and his colleagues showed in a clinical study that early high plasma cyst(e)ine level 
(within 24 hours of stroke onset) may predict poor clinical outcome in patients with acute 
stroke(Wong et al., 2006). Precisely, early plasma cyst(e)ine levels were significantly correlated 
with long-term clinical outcome (assessed at 3 months) as well as early stroke deterioration. 
They confirmed this relation in a rat stroke model, showing that administration of cysteine 
increased the infarct volume in a dose-dependent manner. This effect of cysteine was abolished 
by a CBS inhibitor, aminooxyacetic acid, indicating that hydrogen sulfide may be involved in 
ischemic brain damage. In another study, Wong‟s group showed that hydrogen sulfide 
production by 3-Mercaptopyruvate sulfurtransferase (3MST) was downregulated after stroke in 
astrocytes, suggesting that the elevated hydrogen sulfide level was mainly mediated by CBS 
(Zhao, Chan, Ng, & Wong, 2013). The detrimental effect of hydrogen sulfide was further 
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confirmed by Wong‟s group using a permanent occlusion of the middle cerebral artery model 
(pMCAO) (K. Qu et al., 2006), which is a classical in vitro model for ischemic stroke. According 
to their discovery, MCAO increased hydrogen sulfide level and hydrogen sulfide synthesizing 
activity in the cortex. And MCAO-induced infarct volume was reduced dose dependently by four 
different inhibitors of hydrogen sulfide synthesis enzymes, while significantly increased by 
administration of NaHS. 
However, these findings have been challenged by more recent discoveries. Our group found 
that hydrogen sulfide could protect neurons against hypoxic injury (Tay et al., 2010). It was also 
shown that hydrogen sulfide -induced long-term (2 days) hypothermia reduced infarct volume in 
aged rats after focal ischemia caused by reversible occlusion of the right middle cerebral artery 
(Florian et al., 2008). Similarly, Gheibi  et al. reported that treatment with hydrogen sulfide 
reduced brain injuries and postischemic cerebral edema in a dose-dependent manner in a 
transient model of focal cerebral ischemia likely via blocking programmed cell death (Gheibi et 
al., 2014). Additionally, Wang et al. reported that hydrogen sulfide protected blood-brain barrier 
integrity after focal cerebral ischemia followed by reperfusion (Y. Wang et al., 2014). The 
beneficial effects of hydrogen sulfide in global cerebral ischemia were also reported. For 
example, Yin and his colleagues showed that exogenous hydrogen sulfide protected against 
global cerebral ischemia/reperfusion injury in rats via multiple mechanisms, including its anti-
oxidative, anti-inflammatory and anti-apoptotic effects (Yin et al., 2013). Hydrogen sulfide was 
also found to attenuate cognitive deficits by improving the survival rate of hippocampal neurons 
in a four-vessel occlusion model in rats (Wen et al., 2014). In addition to these discoveries 
focusing on the neuroprotective effects of hydrogen sulfide during or shortly after cerebral 
ischemia/reperfusion, it was also reported that treatment with hydrogen sulfide augmented 
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angiogenesis in the peri-infarct area, and significantly improved functional outcomes after 2 
weeks in a rat MCAO model(Jang et al., 2014), suggesting its potential value in regenerative 
recovery after stroke. 
Different hypotheses have been proposed to resolve the seemingly conflict results. In a review 
paper (Gong et al., 2011), we pointed out a few unresolved issues about the early work done by 
Wong PT and Chen CP, which supported the detrimental effects of hydrogen sulfide in stroke, 
including that: (i) sublethal dose of NaHS was employed; (ii) nonspecific CBS inhibitors were 
used; (iii) the causality between stroke and endogenous hydrogen sulfide level elevation remains 
to be assessed in future. It seems that the first issue has been answered by Li  and his colleagues, 
who reported dual effects of hydrogen sulfide on focal cerebral ischaemic injury, where low-dose 
(2.8 mg/kg) NaHS ameliorated MCAO-induced injury while high-dose (11.2 mg/kg) aggravated 
it (G. F. Li et al., 2012). These concentrations seem to be in line with the different concentrations 
used in experiments giving rise to conflicting results, though it‟s still uncertain whether the 
conflicts can be fully answered by this discovery. Since stroke is a complex disease where 
several lines of pathological processes occur and interact with each other in a complex way, it‟s 
possible that hydrogen sulfide may play different roles in this dynamic process, and more 
investigations are required to gain a better understanding of it. 
1.4.5 Effects of hydrogen sulfide on NKA regulation 
It is reported that hydrogen sulfide could decrease NKA currents in pulmonary epithelial cells 
(Althaus et al., 2012; Erb & Althaus, 2014). Specifically, hydrogen sulfide rapidly and reversibly 
inhibited Na
+
 transport. Hydrogen sulfide had no effect on Na
+
 channels, whereas it decreased 
NKA currents. Hydrogen sulfide did not affect the membrane abundance of NKA, its metabolic 
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or calcium-dependent regulation, or its intrinsic activity. However, hydrogen sulfide inhibited 
basolateral calcium-dependent K
+
 channels, which consequently decreased Na
+
 absorption 
because NKA reaction cycle was dependent on K
+
 availability. 
Another study showed that hydrogen sulfide down-regulated NKA function through inducing 
NKA endocytosis in renal tubular epithelial cells (Ge et al., 2014). According to their data, 
hydrogen sulfide targeted EGFR Cys797/Cys798 residues, thus activating the 
EGFR/gab1/PI3K/Akt pathway and subsequent NKA endocytosis. 
These studies suggest that hydrogen sulfide may influence NKA functions either directly or 
indirectly. So far no evidences in the CNS have been reported. It remains elusive whether similar 
effects exist in brains under healthy or pathological conditions. 
1.4.6 ADTOH-DSS, a novel hydrogen sulfide donor 
To exploit the therapeutic effects of hydrogen sulfide, several groups are working on 
hydrogen sulfide slow releasing compounds, with the hope of finding better “drug-like” 
compounds. These attempts include GYY4137 (Y. Kimura et al., 2013), ACS14 (Sparatore et al., 
2009) and so on. Their therapeutic values have been demonstrated in vitro or in animal models 
(Osborne, Ji, Majid, Del Soldata, & Sparatore, 2012; H. Y. Yang et al., 2014). However, more 
investigation is still needed to study the potential toxic effects after long term treatment with 
these hydrogen sulfide -releasing compounds.  
ADTOH-DSS or ADT-DSS (Figure 1.2) is a novel hydrogen sulfide slow-releasing 
compound synthesized by our group. It consists two parts, danshensu (β-3, 4-dihydroxyphenyl-
lactic acid, DSS) and ADTOH [5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione]. Danshensu 
(DSS) is a water-soluble compound extracted from Radix Salviae miltiorrhizae (a traditional 
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Chinese herb known as „Danshen‟). It has been used in China for the treatment with 
microcirculatory disturbance-related diseases. DSS has biological activities such as anti-
inflammation, anti-apoptosis and suppressing ROS formation. ADTOH is a hydrogen sulfide -
releasing moiety used in several hydrogen sulfide slow-releasing compounds such as ACS14, 
ACS15 (Giustarini, Del Soldato, Sparatore, & Rossi, 2010). It has undergone several human 
trials in order to test their chemopreventive efficacy. An increase of hydrogen sulfide has been 
detected in several rat tissues after administration of nonsteroidal anti-inflammatory drugs 
containing ADTOH (L. Li et al., 2007). Our unpublished data showed that ADTOH began to 
release from DSS soon after the compound is i.v. injected to animals, thus allowing the two 










1.5 Objectives and significance of the present study 
Studies have shown that NKA function is suppressed in ischemic stroke and involved in 
pathogenesis of ischemia/reperfusion-induced injuries. An antibody (DR-Ab) targeting the DR-
region of NKA was developed by our group. We therefore wonder whether this antibody can be 
used as a potential neuroprotectant in ischemic stroke through activating or preserving NKA 
activity. 
On the other hand, hydrogen sulfide was found to be neuroprotective in several central 
nervous system diseases. But conflicting results about the roles of hydrogen sulfide in ischemic 
stroke were reported. Additionally, it is reported that hydrogen sulfide could decrease NKA 
activity in pulmonary epithelial cells (Althaus et al., 2012; Erb & Althaus, 2014), and down-
regulate NKA function through inducing NKA endocytosis in renal tubular epithelial cells (Ge et 
al., 2014). In order to exploit the possible neuroprotective effects of hydrogen sulfide, we 
synthesized a novel hydrogen sulfide slow-releasing compound, ADTOH-DSS, which consists of 
a hydrogen sulfide releasing moiety (ADTOH) and a neuroprotective pharmacophore (DSS). 
Thus we want to know whether this compound can also modulate NKA function in the context of 
cerebral ischemia, and more importantly, whether it can play beneficial effects in ischemic stroke. 
For these objectives, we examined the effects of DR-Ab and ADTOH-DSS in a tMCAO 
model of mice. We also tested the effects of DR-Ab in an oxygen glucose deprivation (OGD) 
model and a glutamate-induced excitotoxicity model in human neuronal SH-SY5Y cells.  
The findings from the current study are expected to contribute to the knowledge in these areas: 
the pathophysiological roles of NKA in ischemic stroke, the pharmacological effects of DR-Ab 
and ADTOH-DSS in ischemic stroke, the potential effect of hydrogen sulfide on NKA activity in 
ischemic conditions. This study may possibly serve as a “target validation” study of the NKA in 
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ischemic stroke treatment, and may contribute to both basic science and translational studies 
about NKA.  
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Chapter 2 Methods 
2.1 Animals 
All experiments were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health [NIH Publication No. 85 
(23), revised 1996]. The animal study protocols were approved by the Institutional Animal Care 
and Use Committees of National University of Singapore. 
2.2 Generation of DR-Ab 





biweekly for four times. The initial dose was 200 µg protein emulsified with complete Freund‟s 
adjuvant (CFA) followed by 100 µg protein emulsified with IFA (incomplete Freund‟s adjuvant) 
per rat every two weeks. 5 days after the last immunization, serum was collected. Antibody was 
purified by Protein L resin column and the titer was detected by ELISA against DR peptides.  
After purification of DR-Ab from immunized sera, the binding of DR-Ab to NKA was 
confirmed with Western blots. Our antibody specifically detected the bands of NKA similarly to 
commercial NKA antibodies. 
2.3 Middle cerebral artery occlusion model (MCAO) 
Transient MCAO was performed in 5-6 week old male C57Bl/6 mice (20-25 g) following the 
method  described by Buchan, A.M. (Buchan, Xue, & Slivka, 1992). Briefly, focal cerebral 
ischemia was induced by occlusion of the middle cerebral artery. Silicon coated monofilament 
(Doccol Corporation) was inserted into the internal carotid and advanced ~10 mm to occlude the 
origin of the MCA. Reperfusion was allowed after 45 min by monofilament removal. Cerebral 
blood flow was determined in the territory of the MCA by laser Doppler flowmetry. DR antibody 
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or normal serum (300 µg/mouse) was administrated by i.c.v. injection 1 h before the surgery 
(pretreatment) or immediately after reperfusion (posttreatment). ADTOH-DSS (0.01g/kg as an 
aqueous suspension) was given 1 h before the surgery (pretreatment) or after reperfusion 
(posttreatment) as soon as they recovered from anesthesia. Animals were sacrificed 24 h after 
surgery. Brains were collected immediately on ice for further experiments. 
2.4 Measurement of infarct volume 
Brain tissues were stained using triphenyl tetrazolium chloride (TTC) to measure the infarct 
volume. Edema corrected infarct volume was measured as (volume of non-lesioned area in the 
contralateral hemisphere – volume of non-lesioned area in the ipsilateral hemisphere) / volume 
of non-lesioned area in the contralateral hemisphere * 100%. The penumbra area of fresh brain 
tissues were collected for Western blot or ELISA assays. 
2.5 Assessment of neurological deficits 
Neurological deficits were scored at 1 and 24 hr post-reperfusion using an expanded six-point 
scale (Rousselet, Kriz, & Seidah, 2012): 
0: normal. 
1: mild circling behavior with or without inconsistent rotation when picked up by the tail, <50% 
attempts to rotate to the contralateral side. 
2: mild consistent circling, >50% attempts to rotate to the contralateral side. 
3: consistent strong and immediate circling, the mouse holds a rotation position for more than 
1-2 sec, with its nose almost reaching its tail. 
4: severe rotation progressing into barreling, loss of walking or righting reflex. 
5: comatose or moribund. 
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2.6 Cell culture 
Human neuroblastoma SH-SY5Y cells were incubated under humidified 5% CO2 and 95% air 
at 37°C in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) containing 
10% fetal bovine serum (FBS) and 1% streptomycin and penicillin (Invitrogen). Cells were 
plated onto 35mm dishes and incubated overnight as they grew into 80%–90% confluency before 
they are subjected to treatments 
2.7 Oxygen glucose deprivation model 
The method for oxygen and glucose deprivation (OGD) treatment was described in our 
previous publication with modification (Tay et al., 2010). Briefly, human neuroblastoma SH-
SY5Y cells were incubated under humidified 5% CO2 and 95% air at 37°C in Dulbecco's 
modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) containing 10% fetal bovine 
serum (FBS) and 1% streptomycin and penicillin (Invitrogen). Cells were plated onto 96-well 
paltes and incubated overnight as they grew into 80%–90% confluency. Then SH-SY5Y cells 
were cultured in glucose-free DMEM and incubated under 5 % CO2 and 1.5% O2 at 37 °C for 
12h in a hypoxic chamber. The control group was cultured in normal media and incubated under 
5 % CO2 and normoxic condition at the same time. Reperfusion was then enabled by transferring 
cells to normal media and incubated under 5 % CO2 and normoxic condition for 24h. DR-Ab or 
normal serum (NS) was added 1h before (pretreatment) and after (posttreatment) OGD treatment. 
Cell viability was then measured by MTT assay. 
2.8 Cell viability assay 
Cell viability was determined by a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazoleum (MTT) assay (Sigma–Aldrich). Briefly, MTT was added to cells at a final 
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concentration of 0.5 mg/ml and the cells were further incubated at 37 °C for 4 h. Then, the 
insoluble formazan was dissolved with dimethyl sulfoxide (DMSO); colorimetric determination 
of MTT reduction was measured at 570 nm with a reference wavelength at 630 nm. Control cells 
were taken as 100% viability. 
2.9 Western blot 
Cells or tissue samples were homogenized in tissue lysis buffer (1:10, w/v; Sigma). The lysate 
was shaken on ice for 1 h, then centrifuged at 12 000  g at 4°C for 15 min. Epitopes were 
exposed by boiling the protein samples at 100°C water for 5 min. Protein concentrations were 
determined with NanoDrop Spectrophotometer (NanoDrop technology, USA). Equal amounts of 
the protein samples were separated by electrophoresis using a 10% sodium dodecyl 
sulphate/polyacrylamide gel (SDS/PAGE) and transferred onto a nitrocellulose membrane 
(Whatman, UK). After being blocked in 10% milk with TBS-T (Tris buffer saline-Tween 20) 
buffer (10 mM Tris-HCl, 120 mM NaCl, 0.1% Tween-20, pH 7.4) at room temperature for 1 h, 
the membrane was incubated with various primary antibodies including caspase 8, caspase 9, 
cleaved caspase 8, cleaved caspase 9, cox-2 (1:1000, Cell Signalling, USA) at 4°C overnight. 
Beta-actin (1:5000, Santa Cruz) was used as a loading control. Membranes were washed three 
times in TBS-T buffer, followed by incubation with goat anti-rabbit or goat anti-mouse 
secondary antibodies (1:10 000, Santa Cruz) at room temperature for 1 h, and washed three times 
in TBS-T buffer. Visualization was carried out using ECL
®
 (plus/advanced chemiluminescence) 
kit (GE Healthcare Life Sciences, UK). The density of the bands on Western blots was quantified 
by Image J software (USA). 
2.10 Enzyme-linked immunosorbent assay 
Brain tissues were collected and processed as described above. The resultant supernatant was 
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collected for cytokine (IL-1β and IL-6) concentration determination using enzyme-linked 
immunosorbent assay set from Biomed Diagnostics (BD Biosciences). The cytokine levels in 
each tissue sample (in picograms/milliliter) were then normalized to the protein concentration 
(milligrams/milliliter) of each tissue sample to give a final cytokine result expressed as 
picograms/milligram of protein. 
2.11 Measurements of intracellular calcium level ([Ca2+]i) in neurons 
Adherent cells cultured on sterilized coverslips were incubated with 4 μM fura-2/AM for 30 
min in DMEM. The unincorporated dye was removed by washing the cells twice in fresh 
incubation solution. Loaded cells were maintained at room temperature for 30 min before 
measurements of [Ca
2+
]i in order to allow any fura-2/AM in the cytosol to de-esterify. Cells 
loaded with fura-2/AM were transferred to the stage of an inverted microscope (Nikon Ltd., 
Japan) in a superfusion chamber at room temperature. The inverted microscope was coupled with 
a dual-wavelength excitation spectrofluorometer (Intracellular Imaging Inc, USA). Cells were 
perfused with Krebs‟ bicarbonate buffer (KB buffer, mM; 117 NaCl, 5 KCl, 1.2 MgSO4, 1.2 
KH2PO4, 1.25 CaCl2, 25 NaHCO3, 11 glucose, pH 7.4) or EGTA-treated calcium-free Kreb's 
bicarbonate buffer (mM; 2 EGTA, 117 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 11 
glucose, pH 7.4). Drugs were added directly into the bathing solution during calcium 
measurement and the change in fluorescent intensity was monitored. The ratio of fluorescent 
signals obtained at 340 nm (F340) and 380 nm (F380) excitation wavelengths were recorded. 
F340/F380 ratio was used to represent the [Ca
2+
]i in the cells.  
2.12 NKA activity assay 
The NKA activity was detected using the SensoLyte® FDP Protein Phosphatase Assay Kit 
(AnaSpec, Inc.) following the manufacturer's instructions. Briefly, cell or tissue lysates were 
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added to black 96-well plates (50µl/well). 50µl of the FDP reaction solution was added to each 
well. Reaction was initiated by 10 mM KCl. Fluorescence intensity was measured 10min after 
initiation of reaction at Ex/Em=490/520 nm. 
2.13 Statistics 
Values presented are mean ± standard error of mean. GraphPad Prism for Windows (5.01. 
GraphPad Software, Inc, USA) was used to perform the analysis. One-way analysis of variance 
(ANOVA) was employed to determine the difference among groups. Bonferroni test was used to 




Chapter 3 Therapeutic effect of DR-Ab in in tMCAO mice: Pretreatment 
3.1 Introduction 
NKA is ubiquitously expressed in almost all animal cells and plays an important role in 
maintaining normal cell health and functions. Cells have a high intracellular K
+
 concentration 
and a high extracellular Na
+
 concentration in resting conditions. Na
+
 ions constantly leaks into 
cells and K
+





 ions against the electrochemical potential and maintains normal ion 
gradients. And the active removal of intracellular Ca
2+




 exchanger also relies on 
the cross-membrane Na
+
 gradient to carry on. The direction of this process can even be reversed 
as a result of Na
+
 dysregulation (D. I. Lee et al., 2009). Neuronal are especially dependent on the 
proper function of NKA. In most animal cells, the NKA is responsible for about 1/5 of the cell's 
energy expenditure. But for neurons, the NKA can be responsible for up to 2/3 of the cell's 
energy expenditure (Sheldon et al., 2004). 
In ischemic stroke, blood flow is either temperately or permanently interrupted. This leads to 
a shortage of glucose and oxygen in the tissues being influenced. Neuronal cells almost totally 
rely on aerobic respiration for energy. The ischemia-induced energy failure hampers the ability 




 ions (Xu et al., 2006). High concentration of these 
cations in cells may result in membrane depolarization, which promotes activation of synaptic 
glutamate receptors and finally causes excitotoxicity (Dirnagl et al., 1999). From this perspective, 
the malfunction of NKA is indeed a gateway of the “ischemic cascades”. 
The function of NKA is dramatically suppressed in ischemic or hypoxic conditions. This is 
not fully because of the aforementioned energy failure. Indeed, both NKA levels and activity are 
downregulated in models of focal ischemia and traumatic brain injury (Jamme et al., 1997; Jung 
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et al., 2007; Tavalin et al., 1997). This fact suggests that pharmacologically preserving NKA 
function is possible in the context of partial energy failure in ischemia. Actually it has been 
reported that low-concentration ouabain is able to stimulate NKA activity and exert a protective 
effect in ischemic stroke (J. K. Wang et al., 2006). We also showed that our DR-Ab was able to 
increase NKA activity and protected isolated ventricular myocytes from ischemia/reperfusion 
injuries (Zheng et al., 2011). We therefore hypothesized that DR-Ab may reduce 
ischemia/reperfusion induced injuries in the brain, and tested this hypothesis in a tMCAO model 
of ischemic stroke in mice. 
3.2 Results 
3.2.1 Pretreatment with DR-Ab decreases infarct volumes in tMCAO mice 
Transient MCAO was performed in 5-6 week old male C57Bl/6 mice (20-25 g). Reperfusion 
was allowed after 45 min by monofilament removal. DR antibody or normal serum (300 
µg/mouse) was administrated by i.c.v. injection 1 h before the surgery (pretreatment). Animals 
were sacrificed 24 h after surgery. As shown in Figure 3.1, brain infraction was successfully 
induced in tMCAO mice but not in the sham group, indicating the success of the model. 
Pretreatment with DR antibody 1h before the onset of stroke significantly (p=0.010) reduced the 
infarct volume measured at 24h after surgery, which dropped from 39.7±1.9% of contralateral in 









Figure 3.1. Effects of DR-Ab pretreatment on infarct volumes in tMCAO mice. Pretreatment 
with DR-Ab decreased infarct volume induced by tMCAO (45min ischemia followed by 24h 
reperfusion). Representative pictures (A) and group data (B) showing that pretreatment with DR 
antibody (300µg/mouse, i.c.v.) significantly reduced the infarct volume. Mean±SEM. n=5-6. * 




3.2.2 Pretreatment with DR-Ab does not significantly change neurological 
deficits in tMCAO mice 
The neurological deficits were scored 1h and 24h after surgery. As shown in Figure 3.2, the 
neurological scores assessed at 1h post-surgery were very similar in both treatment groups, 
suggesting that the differences in the severity of damage, if any, were not as evident as that at the 
behavior level at this very early time, thus allowing for a comparable start point for both groups. 
The neurological deficits at 24h post-surgery were less severe, although insignificantly, in the 
DR-treated group than those in the NS-treated group. These data suggest an unconfirmed 



































3.2.3 Pretreatment with DR-Ab protects SH-SY5Y cells from OGD/R insults 
Human neuronal SH-SY5Y cells were exposed to oxygen-glucose deprivation/reperfusion 
insults consisting of 12h OGD treatment followed by 24h reperfusion. Cell viability was 
measured using MTT assay. As shown in Figure 3.3, OGD/R significantly decreased cell 
viability to roughly 35% of control. NS pretreatment (1h before OGD) did not significantly 
change the cell viability compared to the OGD/R group. DR-Ab significantly reversed the cell 















































Figure 3.3. Pretreatment with DR-Ab protected SH-SY5Y cells from OGD/R insults. Cells 
were treated with oxygen and glucose deprivation (OGD) for 12 h followed by reperfusion for 24 
h (OGD+R). DR-Ab (2 μM) was given 1 h before OGD/R. Same amount of normal serum (NS) 
was given in similar ways (NS+OGDR). Mean±SEM. n=6. ***p<0.001 vs CON group. ns, not 






In this study, it was found that pretreatment with a NKA-stimulating agent, DR-Ab, was able 
to increase the ability of cerebral cells or tissues to tolerate injuries induced by 
ischemia/reperfusion. Precisely, pretreatment with DR-Ab 1h before onset of cerebral ischemia 
led to a dramatic reduction in the infarct volumes and an insignificant decrease in neurological 
deficits observed at 24h post-surgery in tMCAO mice compared to NS. Consistently, 
administration of DR-Ab 1h before OGD also caused better cell viability than NS in human 
neuronal SH-SY5Y cells. These results collectively suggest that stimulation of NKA with DR-
Ab was a possible neuroprotective strategy against ischemia/reperfusion injuries. 
This is consistent with earlier studies on the roles of this antibody in ischemic hearts (Zheng 
et al., 2011). Specifically, our group showed that DR-Ab was able to prolong survival time of 
isolated cardiomyocytes, preserved cell viability in isolated ventricular myocytes subjected to 
ischemia/reperfusion, and had cardioprotective effects in isolated hearts subjected to 
ischemia/reperfusion. NKA stimulation as a neuroprotective strategy was also supported by 
another group using a different stimulating agent. Oselkin M, et al showed that low-dose 
cardiotonic steroids increased NKA activity. More importantly, ouabain protected slice culture 
neurons from experimental ischemia at concentrations that increase NKA activity but not at 
higher concentrations that inhibit NKA activity (J. K. Wang et al., 2006). 
Nevertheless, evidences supporting NKA inhibition as a neuroprotective strategy were also 
reported. For example, it was reported that ouabain pretreatment protected neurons from OGD 
insults (Bruer et al., 1997). Another group showed that cardiac glycosides provided 
neuroprotection against ischemic stroke using a brain slice-based compound screening platform 
(J. K. Wang et al., 2006). These seemingly conflict results are possibly due to several reasons. 
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For one thing, MCAO model, the animal model that best mimics real ischemic stroke, was not 
conducted in these studies. The models they adopted may emphasize on different aspects of 
ischemic stroke and lead to inconsistent results than others. Additionally, it was found that 
ouabain may stimulate NKA at low concentrations but inhibit it at higher concentrations 
(Oselkin et al., 2010). The exact effect of ouabain on NKA activity was not demonstrated in 
these studies. Finally, both ouabain and DR-Ab have been found to stimulate signaling pathways 
independent of its ion transporting functions. These functions may also contribute to the 
aforementioned conflicts. To answer the latter two questions, we examined the effects of DR-Ab 
on NKA activity and signaling functions in further studies. 
It is note-worthy that the difference in neurological deficits in the present study was less 
obvious than that of infarct volumes or cell viability. It is true that functional outcomes are less 
sensitive to treatments than parameters focusing on damages at the cellular or tissue levels in 
both human patients and animal models, which might explains the less significant difference in 




Chapter 4 DR-Ab protects SH-SY5Y cells against glutamate-induced 
excitotoxicity 
4.1 Introduction 
In order to understand how DR-Ab exerts the protective effects in ischemic stroke, we 
examined the role of DR-Ab in excitotoxicity, which is an important pathological event in the 
acute and subacute phase of ischemic stroke. Excitotoxicity is the pathological process by which 
nerve cells are damaged and killed by excessive stimulation by neurotransmitters such as 
glutamate and similar substances. This occurs when receptors for the excitatory neurotransmitter 
glutamate (glutamate receptors) such as the NMDA receptor and AMPA receptor are 
overactivated by glutamatergic storm. Overactivation of these receptors increases membrane 
permeability to Ca
2+
 ions and allows Ca
2+
 to influx in a large quantity. As a universal second 
messenger, Ca
2+
 overload is able to activate a series of destructive enzymes such as proteases, 
lipases, and endonucleases. These enzymes may cause permanent damage to cells, leading to cell 
death or loss of cellular integrity. Pro-inflammatory components may be released from dead or 
damaged cells, which lead to more diverse detrimental pathological events (Dirnagl et al., 1999). 





 ions may cause loss of resting potential and increase of excitability. 
Excessive excitation activates voltage-dependent Ca
2+
 channels and release of excitatory amino 
acids such as glutamate and aspartate. In normal conditions, extracellular glutamate is cleared by 
astrocytes by activate uptake. This is an energy-dependent process and relies on the cross-
membrane sodium gradient. In ischemic conditions, sodium influx causes cessation or even 
reversal of the normal process of glutamate uptake by astrocyte glutamate transporters (Grewer 
et al., 2008; Rossi et al., 2000; Szatkowski et al., 1990). As a result of its increased release and 
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decreased uptake, glutamate accumulates to excessive levels in extracellular space. 
Accumulation of extracellular glutamate causes activation of N-methyl-D-aspartate (NMDA) 
receptors, the alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and 
metabotropic glutamate receptors, and ultimately leads to excitotoxicity (Dirnagl et al., 1999). 
NKA is expected to influence this process in several ways. First, if the function of NKA is 
preserved in cerebral ischemia, membrane potentials of cells are more likely to be stabilized. 
Secondly, NKA maintains the cross-membrane Na
+
 gradient and thus the driving force for active 
glutamate transport in astrocytes. So stimulation of NKA in astrocytes may help to ameliorate 





 exchanger are functionally coupled. Pharmacological inhibition of NKA has been 
proved as a useful strategy for suppressing Ca
2+
 extrusion in the cardiovascular system for long. 
So it is reasonable to ask whether an opposite strategy, i.e. boosting Ca
2+
 clearance by 
stimulating NKA, is effective in neuronal cells in excitotoxicity. Hence the effect of NKA 
stimulation using DR-Ab on exicitotoxicity was tested in this study. For reasons of specificity 
and convenience, I adopted an in vitro model using glutamate to induce excitotoxicity in human 
neuronal SH-SY5Y cells. 
4.2 Results 
4.2.1 Pretreatment with DR-Ab prevents SH-SY5Y cells against glutamate-
induced cell injury 
Glutamate was used to induce excitotoxicity in human neuronal SH-SY5Y cells. As shown in 
Figure 4.1A, glutamate dose-dependently decreased cell viability. This effect became saturated 
as the concentration excelled 100µM. Thus this concentration was chosen for further 
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experiments. As shown in Figure 4.1, DR-Ab significantly ameliorated the damage induced by 
























































































Figure 4.1. Protective effects of DR-Ab against cell injury caused by ischemic insults. A. 
Cells were treated with different concentration of glutamate (glutamate 10-200 μM + glycine 
10µM in magnesium free solution, 24 h). B. Cells were pretreated with DR-Ab (2 μM, DR) or 
normal serum (NS) 1h before being treated with 100 μM glutamate (glutamate 100 μM + glycine 
10µM in magnesium free solution, 24 h). Mean±SEM. n=6. ***p<0.001 vs Con. ns, not 




4.2.2 Pretreatment with DR-Ab prevents SH-SY5Y cells against glutamate-
suppressed NKA function 
The apparent NKA activity in excitotoxicity was studies using glutamate. As shown in Figure 
4.2, the activity of NKA was decreased in SH-SY5Y cells treated with glutamate. This decrease 





































Figure 4.2. Effect of DR-Ab on NKA activity in glutamate-induced excitotoxicity. A. Cells 
were treated with glutamate (glutamate 100 μM + glycine 10µM in magnesium free solution) for 
24h. DR-Ab (2 μM, DR) or normal serum (NS) were added 1h before cells were treated with 
glutamate. Mean±SEM. n=6. *p<0.05 vs control. ns, not significant (p>0.05) vs glutamate group. 




4.2.3 Pretreatment with DR-Ab reduces glutamate-induced calcium overload in 
SH-SY5Y cells 
Figure 4.3 shows that application of 100 μM glutamate to neurons loaded with Fura-2 induced 
sustained intracellular Ca
2+
 responses. Pretreatment with neurons with 2 µM DR-Ab (DR+glu), 
attenuated the calcium overload induced by glutamate. In addition, DR-Ab significantly 
accelerated the decay of intracellular Ca
2+
 concentration. The decay time from peak to 90% of 
baseline level was about 7s in DR-Ab treatment group which is significantly shorter than that in 
the NS group (Fig 4.2 B). These data suggest that DR-Ab can prevent Ca
2+



































Figure 4.3. DR-Ab attenuated the intracellular calcium overload induced by glutamate. (A-
B) Representative calcium tracings (A) and group data (B) showing the effect of DR-Ab on 
calcium overload and the decay time (t90) upon application of glutamate (100 μM). Mean±SEM. 




In this part of the study, we found that DR-Ab pretreatment significantly reversed the cell 
viability loss induced by glutamate at toxic concentrations, suggesting a protective effect of DR-
Ab against excitotoxicity. In the meanwhile, the NKA inhibition caused by glutamate was also 
abolished by DR-Ab treatment in parallel. This association is consistent with the hypothesis that 
DR-Ab may modulate excitotoxicity through preserving or restoring normal NKA activities. 
What's more, we also found that DR-Ab attenuated the intracellular calcium overload induced 





exchanger (NCX) was reported. Precisely, it is well known that the Na
+
 gradient established and 
maintained by NKA was the driving force for NCX to exchange intracellular Ca
2+
 ions for 
extracellular Na
+









 exchanger to prevent Ca
2+
 overload 
and neuronal apoptosis in excitotoxic stress (Sibarov, Bolshakov, Abushik, Krivoi, & Antonov, 
2012). Thus it is reasonable to assume that DR-Ab suppressed the intracellular calcium overload 
via NCX, although we are uncertain whether this is mediated by Na
+
 gradient, the interaction 
between NKA and NCX, or both. 
In summary, this part of the study demonstrated the neuroprotective effect of DR-Ab in 
glutamate-induced excitotoxicity. This effect is possibly mediated by increased intracellular Ca
2+
 
handling in DR-Ab treated cells via association of NKA and NCX. The protective effect against 
excitotoxicity provides a reasonable mechanism of the neuroprotective role of DR-Ab in 
ischemic stroke because of the critical role of excitotoxicity in the development of ischemic 




Chapter 5 Therapeutic effect of DR-Ab in tMCAO mice: Posttreatment  
5.1 Introduction 
While we have shown that pretreatment with DR-Ab played a protective effect in tMCAO 
mice, it is unclear in which time phase or phases the DR-Ab exerted its effects. Especially, 
excitotoxicity occurs quickly after stroke onset, and more pathological processes are triggered 
thereafter. A drug can only be given to patients of ischemic stroke after its onset. Thus 
posttreatment can better fulfill the potential clinical interest associated with this novel 
neuroprotective agent. We showed that DR-Ab pretreatment could suppress excitotoxicity-
induced injuries, yet we wonder whether it can also exert beneficial effects when administrated 
after reperfusion, where more pathological processes are already triggered. In addition to clinical 
significance, a study of its effects in posttreatment also gives a better understanding of the roles 
of NKA in the sub-acute and late phases of ischemia/reperfusion induced cerebral disorders. For 
these reasons we are interested in whether the DR-Ab has therapeutic effects if it is administrated 
after ischemic stroke and reperfusion. 
After reperfusion, the cerebral blood flow returns to normal levels. However, it is found that 
the activity of NKA is not restored to its normal level immediately after reperfusion (Yang et al, 
1992). The pathophysiological consequences of this sustained inhibition in NKA activity are not 
fully understood. In this part of the present study, we are also interested in whether the DR-Ab 
also influences the NKA function after ischemia/reperfusion. 
After excitotoxicity in the initial phase of ischemic cascades, apoptosis and inflammation 
predominate the major pathological processes in later stages after cerebral ischemia/reperfusion  
(Dirnagl et al., 1999). These events can last from hours to days and are considered as potential 
targets for delayed neuroprotection after ischemic stroke. NKA may possibly influence apoptosis 
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and inflammation through its signaling functions. But its association with these processes is 
elusive so far. So we also examined its effects on apoptosis and inflammation after 
ischemic/reperfusion insults. 
5.2 Results 
5.2.1 Posttreatment with DR-Ab reduces infarct volumes in tMCAO mice 
Transient MCAO was performed in 5-6 week old male C57Bl/6 mice (20-25 g). Reperfusion 
was allowed after 45 min by monofilament removal. DR antibody or normal serum (300 
µg/mouse) was administrated by i.c.v. injection immediately after reperfusion (posttreatment). 
Animals were sacrificed 24 h after surgery. As shown in Figure 5.1, brain infraction was 
successfully induced in tMCAO mice but not the sham group, indicating success of the model. 
Posttreatment with DR antibody significantly (p=0.008) reduced the infarct volume measured at 
24h after surgery, which dropped from 34.8±3.3% of contralateral in the NS group to 22.2±1.1% 









Figure 5.1. Effects of DR-Ab postreatment on infarct volumes in tMCAO mice.  
Posttreatment with DR-Ab decreased infarct volume induced by tMCAO (45min ischemia 
followed by reperfusion). Representative pictures (A) and group data (B) showing that 
pretreatment with DR antibody (300µg/mouse, i.c.v.) significantly reduced the infarct volume. 
Mean±SEM. n=5. ** p=0.008 vs NS (normal serum) treatment group.  
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5.2.2 Posttreatment with DR-Ab did not significantly change neurological 
deficits in tMCAO mice 
The neurological deficits were scored 1h and 24h after surgery. As shown in Figure 5.2, the 
neurological scores assessed at 1h post-surgery were very similar in both treatment groups, 
suggesting that the differences in severity of damage, if any, were not evident at the behavior 
level at this very early time, thus allowing for a comparable start point for both groups. The 
neurological deficits at 24h post-surgery were less severe, although insignificantly, in the DR-
treated group than those in the NS-treated group. These data suggest an unconfirmed beneficial 





























Figure 5.2. Effects of DR-Ab posttreatment on neurological deficits induced by tMCAO in 




5.2.3 Posttreatment with DR-Ab attenuates tMCAO-induced apoptosis in mice 
Penumbral region of ischemic brain was isolated for western blot analysis. Caspase 8 and 9 
are cleaved in the process of apoptosis. Thus the ratios of cleaved caspase 8 (or 9) and intact 
caspase 8 (or 9) are used as markers of apoptosis level. As shown in Figure 5.3, the ratios of 
caspase 8 and 9 were apparently reduced in DR-Ab treated mice compared with those in the NS 
treated group. This clearly indicates that DR-Ab can inhibit neuronal apoptosis induced by 
ischemic insults. 
 
Figure 5.3. DR-Ab reduced apoptotic protein (caspase 8 & 9) cleavage in penumbral region 




5.2.4 Posttreatment with DR-Ab suppresses tMCAO-induced inflammation in 
mice 
As show in Figure 5.4, DR-Ab significantly attenuated the production of pro-inflammatory 
cytokines such as IL-1β and IL-6 induced by tMCAO in the ischemic penumbra. Likewise, it 
also reverted the tMCAO-induced upregulation of prostaglandin-endoperoxide synthase 2 (cox-
2), which is crucial for neuroinflammation activation. 
 
Figure 5.4. DR-Ab suppressed the inflammation responses after tMCAO in mice. (A)(B) 
DR-Ab significantly ameliorated the production of IL-1β and IL-6 induced by tMCAO in the 
ischemic penumbra. (Mean±SEM. n=4. ** p<0.01 vs sham. # p<0.05 vs NS.) (C) DR-Ab 
suppressed the production of cox-2 induced by tMCAO in the ischemic penumbra. 




5.2.5 Posttreatment with DR-Ab reverses tMCAO-induced NKA function loss in 
mice 
As shown in Figure 5.5, the activity of NKA was decreased in the penumbral areas of mouse 
brains after tMCAO. This decrease, however, was reversed by DR-Ab posttreatment, suggesting 
that DR-Ab was able to preserve the NKA function in I/R insults These data imply that DR-Ab 





























Figure 5.5. DR-Ab reversed the decreased NKA activity induced by tMCAO. NKA activity 
was significantly reduced in tMCAO mice brains while DR-Ab reversed this effect (Mean±SEM. 




5.2.6 Posttreatment with DR-Ab protected SH-SY5Y cells against OGD/R 
insults 
Human neuronal SH-SY5Y cells were exposed to oxygen-glucose deprivation/reperfusion 
insults consisting of 12h OGD treatment followed by 24h reperfusion. Cell viability was 
measured using MTT assay. As shown in Figure 5.6, OGD/R significantly decreased cell  
viability to roughly 35% of control. NS posttreatment (upon reperfusion) did not significantly 
change the cell viability compared to the OGD/R group. DR-Ab significantly reversed the cell 














































Figure 5.6. Posttreatment with DR-Ab protected SH-SY5Y cells from OGD/R insults. Cells 
were treated with oxygen and glucose deprivation (OGD) for 12 h followed by reperfusion for 24 
h (OGD+R). DR-Ab (2 μM) was given upon reperfusion. Same amount of normal serum (NS) 
was given in similar ways (NS+OGDR). Mean±SEM. n=6. ***p<0.001 vs control. ns, not 






In ischemic stroke, a well-recognized principle is “time is brain”. The ischemic penumbra is 
salvageable for up to a few hours but may shrink as ischemia sustains. It is not uncommon to 
find a compound effective in pretreatment but not in posttreatment. Indeed, the only FDA 
approved drug for acute ischemic stroke, rt-PA has well-proved effects only in patients within 3h 
after onset of stroke symptoms ("Tissue plasminogen activator for acute ischemic stroke. The 
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group," 1995). After 
this narrow therapeutic time window, the beneficial effects decrease quickly (Wardlaw et al., 
2012; Zhang et al., 2011). In fact, only small portion of ischemic stroke patients get thrombolysis 
because they are presented to hospital too late (Donnan et al., 2008). Tremendous efforts in 
public health systems and health education have been done to improve timely hospitalization of 
patients (Gilligan et al., 2005). This also highlights the value of effective delayed treatment in 
ischemic stroke. Thus it is also recommended by the stroke therapy academic industry roundtable 
(STAIR) recommendations that effects of posttreatment should be studied before a potential 
compound is subjected to further drug development investigations (Fisher et al., 2009). 
Therefore we examined the effects of DR-Ab when administrated after reperfusion. 
Consistent with its effects in pretreatment, we found it significantly reduced infarct volumes, and 
improved functional outcomes (though insignificantly) in tMCAO mice. Similarly, it also 
rescued SH-SY5Y cells from OGD/R induced injury. These results strongly suggest that DR-Ab 
can serve as a neuroprotectant in ischemic stroke. 
We also measured the NKA activity in brain tissues treated by DR-Ab. As expected, 
ischemia/reperfusion caused a sustained NKA inhibition that could be clearly observed 24h post 
surgery. More importantly, our results show that posttreatment with DR-Ab was also able to 
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reverse this NKA inhibition. 
In addition to damages directly caused by ischemia in the acute phase, secondary injuries 
were caused by prolonged pathophysiological responses. Apoptosis and inflammation play 
important roles in the subacute and later phases of ischemia/reperfusion-induced injuries. Hence 
I measured the levels of apoptosis and inflammation in the penumbral area at 24h post 
reperfusion. The results show that tMCAO significantly elevated apoptosis markers such as 
caspase-8 and caspase-9, and production of pro-inflammatory cytokines such as IL-1beta and IL-
6, and expression of Cox-2, which is critical for inflammation responses. However, post-
treatment with DR-Ab suppressed apoptosis and these inflammatory responses. These data 
suggest that DR-Ab may possibly exert neuroprotection by suppressing apoptosis and 
inflammation, although it remains unknown how NKA is related to these pathological processes.  
It is well-accepted that excessive inflammation is a detrimental factor that profoundly 
exacerbates ischemia/reperfusion-induced injury. But on the other hand, the inflammation 
response also serves as a strong signal for induction of many beneficial events in the transition 
from injury to recovery after cerebral ischemia/reperfusion, such as angiogenesis and 
neurogenesis (Chamorro & Hallenbeck, 2006). It is interesting to examine whether DR-Ab may 
influence these events and thus stroke prognosis. 
In summary, this part of the study showed that posttreatment with DR-Ab protected mice 
against tMCAO-induced injury, which was accompanied with elevated NKA activity, reduced 
inflammation and decreased apoptosis. Similar protective effects were also found in oxygen 
glucose deprivation models in neuronal SH-SY5Y cells. These data collectively suggest that the 




Chapter 6 Effect of ADTOH-DSS on ischemic stroke 
6.1 Introduction 
As an antibody, the in vitro distribution and metabolism of DR-Ab are expected to differ from 
small-molecular compounds significantly. Due to the blood brain barrier, the peripheral 
concentration of DR-Ab may be much higher when it reaches the therapeutic concentration in the 
brain. Because NKA is extensively expressed in almost all cells and is responsible for house-
keeping functions, high peripheral concentration may become a safety concern and restricts its 
potential value as a neuroprotectant. 
Hydrogen sulfide is a small gaseous molecule with diverse pathophysiological functions. It is 
reported that hydrogen sulfide could decrease NKA currents in pulmonary epithelial cells 
(Althaus et al., 2012; Erb & Althaus, 2014), and down-regulate NKA function through inducing 
NKA endocytosis in renal tubular epithelial cells (Ge et al., 2014). Although these effects are 
different from our NKA stimulation strategy, we wonder whether NKA inhibition mediated by 
hydrogen sulfide can produce any effect on ischemic stroke. 
On the other hand, conflicting results have been reported about the role of hydrogen sulfide in 
the ischemic stroke. Hydrogen sulfide was first found to be detrimental in ischemic stroke, 
supported by observational clinical studies in patients (Wong et al., 2006) and confirmed in mice 
using a permanent MCAO model (K. Qu et al., 2006). However, later studies using reduced 
dosages and tMCAO models showed potential beneficial effects of hydrogen sulfide (Gheibi et 
al., 2014; Y. Wang et al., 2014). So we propose that hydrogen sulfide slow-releasing compounds 
may be a better choice than hydrogen sulfide as a neuroprotectant in ischemic stroke. 
Keeping these questions in mind, we synthesized a hydrogen sulfide-releasing compound by 
linking ADTOH and danshensu together. ADTOH is a hydrogen sulfide-releasing moiety used in 
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several hydrogen sulfide slow-releasing compounds such as ACS14, ACS15 (Giustarini et al., 
2010). Studies showed that an increase of H2S can detected in several rat tissues after 
administration of nonsteroidal anti-inflammatory drugs containing ADTOH (L. Li et al., 2007). 
Our unpublished data confirmed that ADTOH began to release from DSS soon after the 
compound is i.v. injected to animals, thus allowing the two components to function 
independently in vitro. 
Danshensu (DSS) is a water-soluble compound extracted from Radix Salviae miltiorrhizae (a 
traditional Chinese herb known as „Danshen‟). It has been used in China for the treatment with 
microcirculatory disturbance-related diseases (Yu et al., 2014). DSS has biological activities 
such as anti-inflammation, anti-apoptosis and suppressing ROS formation (W. Qu, Huang, Li, & 
Qin, 2014). Thus we expect that the combined compound may exhibit better effects than single 
ones by exploiting the neuroprotective effects of both components.  
Therefore we examined the roles of this novel hydrogen sulfide slow-releasing compound, 
ADTOH-DSS, as well as its effects on NKA functions, in ischemic stroke. 
6.2 Results 
6.2.1 Pretreatment with ADTOH-DSS protects SH-SY5Y cells from OGD/R-
induced injuries. 
Human neuronal SH-SY5Y cells were exposed to oxygen-glucose deprivation/reperfusion 
insults consisting of 12h OGD treatment followed by 24h reperfusion. Cell viability was 
measured using MTT assay. As shown in Figure 6.1, OGD/R significantly decreased cell 
viability to roughly 45% of control. ADTOH-DSS pretreatment (1h before OGD) significantly 
















































Figure 6.1. Pretreatment with ADTOH-DSS protected SH-SY5Y cells from OGD/R insults. 
Cells were treated with oxygen and glucose deprivation (OGD) for 12 h followed by reperfusion 
for 24 h. Different concentrations of ADTOH-DSS (dissolved in DMSO) was given 1 h before 
OGD/R. Mean±SEM. n=9. ***p<0.001 vs control. ###p<0.001 vs 0mM treatment group. 
6.2.2 ADTOH-DSS does not significantly change infarct volumes in tMCAO 
mice 
Transient MCAO was performed in 5-6 week old male C57Bl/6 mice (20-25 g). Reperfusion 
was allowed after 45 min by monofilament removal. ADTOH-DSS (0.01g/kg as an aqueous 
suspension) was given 1 h before the surgery (pretreatment) or after reperfusion (posttreatment) 
as soon as they recovered from anesthesia. Animals were sacrificed 24 h after surgery. As shown 
in Figure 6.2-3, brain infraction was successfully induced in tMCAO mice but not the sham 
group, indicating success of the model. Neither pretreatment nor posttreatment with ADTOH-
DSS significantly changed the infarct volumes measured at 24h after surgery compared with the 













































Figure 6.2. Pretreatment with ADTOH-DSS did not significantly influence infarct volume 
induced by tMCAO in mice. Representative pictures (A) and group data (B) showing that 
pretreatment with ADTOH-DSS (0.01g/kg as an aqueous suspension, oral) did not significantly 














































Figure 6.3. Posttreatment with ADTOH-DSS did not significantly influence infarct volume 
induced by tMCAO in mice. Representative pictures (A) and group data (B) showing that 
posttreatment with ADTOH-DSS (0.01g/kg as an aqueous suspension, oral) did not significantly 




6.2.3 ADTOH-DSS does not significantly change neurological deficits in 
tMCAO mice 
The neurological deficits were scored 1h and 24h after surgery. As shown in Figure 6.4, the 
neurological scores assessed at 1h post-surgery were very similar in both treatment groups, 
suggesting that the differences in severity of damage, if any, were not evident at the behavior 
level at this very early time, thus allowing for a comparable start point for both groups. The 
neurological deficits at 24h post-surgery were comparable in both treatment groups. These data 
suggest that neither pretreatment nor postreatment with ADTOH-DSS significantly influenced 



























































































Figure 6.4. Effects of ADTOH-DSS on neurological deficits induced by tMCAO in mice. 
Neither pretreatment nor postreatment with ADTOH-DSS significantly influenced the functional 




6.2.4 ADTOH-DSS does not significantly alter NKA activity in mice 
The penumbral brain tissue was used for NKA activity measurement. As shown in Figure .., 
NKA activity was significantly suppressed in tMCAO mice. This effect was not affected by 



















































Figure 6.5. Effects of ADTOH-DSS on NKA activity in mice. ADTOH-DSS did not 
significantly change NKA activity in tMCAO mice or sham-treated mice. *p<0.05 vs vehicle-
treated sham group. NS, p>0.05 vs vehicle-treated sham group. ns, p>0.05 vs vehicle treated 





In this study, a novel hydrogen sulfide slow-releasing compound, ADTOH-DSS was tested in 
cell and animal models of ischemic stroke. It was shown that ADTOH-DSS pretreatment 
protected SH-SY5Y cells from OGD/R-induced injuries dose-dependently, suggesting a potential 
neuroprotective effect against ischemic insults. Unfortunately, this effect was not translated into 
a therapeutic effect in tMCAO mice. Experiments in whole animals showed that neither pre- or 
post-treatment with ADTOH-DSS significantly reduced neuronal damage in tMCAO mice. This 
may be caused by several possible reasons. 
First, the in vitro effects could be complicated by absorption, distribution, metabolism and 
elimination of this compound. Both danshensu and ADTOH are water-soluble. But ADTOH-
DSS has very poor solubility in water and almost all biologically safe solvents (such as corn oil, 
PEG), most probably due to introduction of three acetyl groups in the synthesis. The poor 
solubility may limit the absorption and distribution of this compound. Our unpublished data 
showed that a therapeutic concentration in the peripheral system was achievable from oral 
administration similar to the present study. We are uncertain about the concentrations of this 
compound and it metabolites in the CNS. Limited CNS distribution is a barrier for many 
potential neuroprotectants. Unfortunately, we were unable to monitor the concentration of 
ADTOH-DSS or its metabolites in the CNS due to technological restrictions, although 
knowledge about the pharmacokinetic parameters of this compound could significantly enhance 
our understanding of its pharmacodynamics in this study. 
Another possible explanation derives from the complex roles of hydrogen sulfide in ischemic 
stroke. Earlier studies strongly suggest that hydrogen sulfide probably have a concentration-
dependent double-edged effect in ischemic stroke (Gheibi et al., 2014; K. Qu et al., 2006; Y. 
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Wang et al., 2014). Hydrogen sulfide may protect neuronal tissues at lower concentrations and 
exacerbates the damage at higher concentrations. Endogenous production of hydrogen sulfide is 
elevated in ischemic conditions (K. Qu et al., 2006; Wong et al., 2006), thus even slow-releasing 
exogenous donors may possibly increase the in vitro concentration of hydrogen sulfide to a toxic 
level. In this case, detrimental effects may possibly offset potential beneficial effects. Therefore 
more studies are needed to fully explain the effects of hydrogen sulfide in ischemic stroke, as 
well as the feasibility of using hydrogen sulfide-releasing compounds as neuroprotectants. 
It was reported that hydrogen sulfide could decrease NKA currents in pulmonary epithelial 
cells (Althaus et al., 2012; Erb & Althaus, 2014), and down-regulate NKA function through 
inducing NKA endocytosis in renal tubular epithelial cells (Ge et al., 2014). We did not find a 
significant change in the apparent activity of NKA in tMCAO mice treated with ADTOH-DSS or 
vehicle. This may be resulted from differences in cell types and models, or insufficient 
concentration of ADTOH-DSS or its metabolites in the CNS. Hence further investigations are 




Chapter 7 General discussion 
Neuroprotection has been suggested as a potential treatment for ischemic stroke for many 
years (Ginsberg, 2008). Many neuroprotectants targeting different steps of the ischemic cascades 
have been tested but failed (Majid, 2014). Since the ion dysregulation that happens in cerebral 
ischemia is a critical gateway to the divergent pathophysiological processes that ultimately lead 
to permanent injuries (Dirnagl et al., 1999), restoring or maintaining the normal ionic gradient is 
considered a possible strategy for ischemic stroke drug development. These attempts include 
NMDA antagonists, Na
+
 channel blockers and so on (Majid, 2014). Although some of them are 
shown to be effective in preclinical studies, translation into clinical usage was disappointing for 
all of them (Fisher et al., 2009). The reasons underlying the failures of translational studies in the 
field of ischemic stroke are very diverse and controversial. However, some researchers suggested 
that neuroprotectants targeting multiple aspects of the ischemic cascades might be a direction 
worth exploration (Majid, 2014). 
NKA is an important protein for cell health and normal functions (Kaplan, 2002). Its function 
is significantly hampered in ischemic stroke (Jamme et al., 1997; Jung et al., 2007; Tavalin et al., 
1997). The function of NKA is closely related to several nodes of the pathophysiological events 






 overload, loss of normal membrane 
potential, suppressed glutamate uptake, excitotoxicity, etc (Dirnagl et al., 1999). Additionally, 
NKA also plays a role in signaling transduction, which is independent of its ion transporting 
functions (Geering, 2008). It has been shown that DR-Ab was able to protect cardiomyocytes 
from ischemic injury in a phosphoinositide 3-kinase (PI3K)/Akt-dependent manner (Zheng et al., 
2011), which is also an important protective pathway in cerebral ischemia. So we propose that 
DR-Ab may possibly exert multiple beneficial effects in ischemic stroke via modulating ion 
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transport and signaling pathways. 
In this study, both pre- and post-treatment with DR-Ab exerted beneficial effects in tMCAO 
mice, as indicated by the decreased infarct size. Similar effects were also found the in vitro 
OGD/R model. In the OGD/R model, pre- and post-treatment with DR-Ab promoted cell 
viability to comparable levels. These results suggest that DR-Ab was effective even given after 
reperfusion. This is crucial for stroke therapeutics because stroke patients usually receive 
medical care relatively late. The effects of delayed administration of DR-Ab could give 
additional value for its potential therapeutic usage. For this reason, the rest of this study mainly 
focused on the post-treatment. 
To learn the function of NKA in this process, I measured the activity of NKA in the brain 
lysates of ischemic penumbra. The activity of NKA was inhibited in brains of tMCAO mice. 
This inhibition, however, was reversed by DR-Ab treatment, suggesting that DR-Ab was able to 
prohibit the NKA function loss induced by I/R insults. It should be noted that this phenomenon 
was observed in mouse brains 24h after ischemia/reperfusion and may not reveal the dynamic 
changes in NKA functionality during ischemia. Therefore, the effect of DR-Ab on the ion 
transport function of NKA was further studied in an in vitro model of excitotoxicity using 
glutamate. Similarly, DR-Ab treatment preserved the NKA functionality against excitotoxicity 
insults. 
More importantly, it is found that DR-Ab attenuated the intracellular calcium overload 





 exchanger (NCX) was reported before (Sibarov et al., 2012). Precisely, it is well known 
that the Na
+
 gradient established and maintained by NKA was the driving force for NCX to 
exchange intracellular Ca
2+
 ions for extracellular Na
+












exchanger to prevent Ca
2+
 overload and neuronal apoptosis in excitotoxic stress (Sibarov et al., 
2012). Thus it is reasonable to assume that DR-Ab suppressed the intracellular calcium overload 
via NCX, although we are uncertain whether this is mediated by Na
+
 gradient, the interaction 
between NKA and NCX, or both. 
Inflammation is one of the detrimental processes responsible for secondary brain injuries 
following ischemia/reperfusion (Chamorro & Hallenbeck, 2006; Dirnagl et al., 1999). Hence I 
measured the inflammation levels in the penumbral area at 24h post reperfusion. The results 
show that tMCAO significantly elevated production of pro-inflammatory cytokines such as IL-
1beta and IL-6, and expression of Cox-2. However, post-treatment with DR-Ab suppressed these 
inflammatory responses. These data suggest that inflammation is possibly involved in the effects 
of DR-Ab. It is uncertain whether the association between DR-Ab treatment and suppressed 
inflammation is direct or not. More study on this association may contribute to the knowledge on 
the roles of NKA under pathological conditions. However, it is premature to conclude that 
stimulating NKA has anti-inflammatory functions. Besides, it also requires further investigation 
to demonstrate the contribution of inhibited inflammation to the neuroprotection effects of DR-
Ab. 
Earlier studies about the roles of hydrogen sulfide in ischemic stroke showed ambiguous 
results (Gheibi et al., 2014; K. Qu et al., 2006; Y. Wang et al., 2014; Wong et al., 2006). I 
examined the effects of a novel hydrogen sulfide releasing compound, ADTOH-DSS, in an 
OGD/R using SH-SY5Y cells and a tMCAO model using mice. ADTOH-DSS exhibited 
neuroprotective effects in cells but failed to protect animals from experiment ischemic stroke. 
These results suggest that ADTOH-DSS may have a potential neuroprotective effect. But 
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admittedly, it may not be a good therapeutic agent in ischemic stroke. This may be caused by 
poor pharmacokinetic properties or double-edged effects of hydrogen sulfide in ischemic stroke. 
However, more investigations are needed to find the answer. 
Hydrogen sulfide was also reported to influence NKA function in lungs (Althaus et al., 2012; 
Erb & Althaus, 2014) and kidneys (Ge et al., 2014). We did not find similar effects in the brain 
in ischemic conditions. However, due to a lack of knowledge in the pharmacokinetic properties 
of ADTOH-DSS, it is hard to draw a convincing conclusion about the effects of ADTOH-DSS 





Chapter 8 Conclusion 
In this study, the effects of two neuroprotective agents, a NKA stimulating antibody and a 
hydrogen sulfide slow-releasing compound, were tested in ischemic stroke models. It is found 
that pretreatment with the NKA stimulating antibody (DR-Ab) was able to reduce brain injury 
induced by tMCAO in vitro, or cell damage induced by OGD in vitro.  Additionally, 
pretreatment with DR-Ab also protected cells against excitotoxicity, possibly through 
suppression of Ca
2+
 overload, although it is uncertain whether this anti-excitotoxic effect was 
responsible for its protective role in stroke. 
Furthermore, posttreatment with DR-Ab was found to play a therapeutic role in cerebral 
injuries induced by ischemia/reperfusion, as demonstrated by its protective effects in the in vitro 
tMCAO model and the in vitro OGD model. This therapeutic effect was accompanied with 
restoration of normal NKA activity, decreased apoptosis and suppressed inflammation. 
A hydrogen sulfide slow-releasing compound (ADTOH-DSS) was tested in stroke models. It 
exhibited neuroprotective effects in cells but failed to protect animals from experiment ischemic 
stroke. These results suggest that ADTOH-DSS may have a potential neuroprotective effect in 
ischemic conditions. But perhaps this effect could not be translated into therapeutic effects in 
whole animals. 
 We failed to observe modulating effects of ADTOH-DSS on NKA activities in tMCAO mice. 
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